Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Vertex Pharmaceuticals Incorporated
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07349394CT.gov Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants | — | Completed | — | — | — |
NCT06299696CT.gov A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists | — | Completed | — | — | — |
NCT06299709CT.gov A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) | — | Completed | — | — | — |
NCT06154447CT.gov Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | — | Active Not Recruiting | — | — | — |
NCT05844449CT.gov Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older | — | Enrolling By Invitation | — | — | — |
NCT03912233CT.gov A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | — | Completed | — | — | — |
NCT03911713CT.gov A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis | — | Completed | — | — | — |
NCT04732910CT.gov Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators | — | Recruiting | — | — | — |
NCT03224351CT.gov A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis | — | Completed | — | — | — |
NCT03227471CT.gov A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT02971839CT.gov Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Deutivacaftor (this asset) | Vertex Pharmaceuticals Incorporated | P3 | BB · 68 |
| Tezacaftor | Vertex Pharmaceuticals Incorporated | P4 | A |
| Liprotamase | Anthera Pharmaceuticals | P4 | BBB |
| Lumacaftor | Hospices Civils de Lyon | P4 | BBB |
| Ivacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| Elexacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| vx-121 | Vertex Pharmaceuticals Incorporated | P3 | BBB |
| Azithromycin | Hospices Civils de Lyon | P4 | BBB |
| Colistin | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BBB |
+42 more in the Cystic Fibrosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Deutivacaftor in Cystic Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/deutivacaftor-cystic-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →